Fagron announces the acquisition of UCP in North America and FDA inspection update

Core Viewpoint - Fagron has announced the acquisition of University Compounding Pharmacy (UCP) in North America, which will enhance its presence in the pharmaceutical compounding market, particularly in the health and wellness segment [1][3][4]. Group 1: Acquisition Details - The enterprise value of the acquisition is approximately $41.5 million, fully financed through Fagron's own resources, and is subject to customary clearance [5]. - UCP specializes in hormones and urology, and has a strong compliance record, making it a complementary addition to Fagron's existing operations [3][4]. - The acquisition is expected to generate around $25 million in annual revenue, with an EBITDA margin below Fagron's existing group margin, and synergies are anticipated over the next 18–24 months [5]. Group 2: FDA Inspection Update - Fagron's facilities in Wichita and Las Vegas were inspected by the FDA, with no repeated observations from the 2024 inspection in Wichita, indicating successful remediation of prior concerns [2][6]. - Following a new routine inspection, the FDA issued a Form 483 with six observations for Fagron Sterile Services and four observations for the 503B Anazao Health facility in Las Vegas [7]. - The company is committed to addressing the FDA's inspectional observations and is implementing corrective actions to enhance its protocols [8].